IRF3 Protein

IRF3 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IRF3 Protein</th>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser402</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser405</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Thr325</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Ser386</td>
<td>CK2</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TBK1</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">IKKε</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAVS</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">p300/CBP</td>
<td>Co-activator</td>
</tr>
<tr>
<td class="label">HDAC3</td>
<td>Corepressor</td>
</tr>
<tr>
<td class="label">VHL</td>
<td>E3 ligase</td>
</tr>
<tr>
<td class="label">PIAS1</td>
<td>E3 SUMO ligase</td>
</tr>
<tr>
<td class="label">A20</td>
<td>Deubiquitinase</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Neurons](/entities/neurons)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Microglia](/entities/microglia)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Astrocytes](/entities/astrocytes)</td>
<td>Moderate</td>
</tr>
<tr>
<t

IRF3 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IRF3 Protein</th>
</tr>
<tr>
<td class="label">Site</td>
<td>Kinase</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser402</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Ser405</td>
<td>TBK1/IKKε</td>
</tr>
<tr>
<td class="label">Thr325</td>
<td>Unknown</td>
</tr>
<tr>
<td class="label">Ser386</td>
<td>CK2</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TBK1</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">IKKε</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">MAVS</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">p300/CBP</td>
<td>Co-activator</td>
</tr>
<tr>
<td class="label">HDAC3</td>
<td>Corepressor</td>
</tr>
<tr>
<td class="label">VHL</td>
<td>E3 ligase</td>
</tr>
<tr>
<td class="label">PIAS1</td>
<td>E3 SUMO ligase</td>
</tr>
<tr>
<td class="label">A20</td>
<td>Deubiquitinase</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Neurons](/entities/neurons)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Microglia](/entities/microglia)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Astrocytes](/entities/astrocytes)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Oligodendrocytes</td>
<td>Low</td>
</tr>
<tr>
<td class="label">[Pericytes](/cell-types/pericytes)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">326 edges</a></td>
</tr>
</table>

Pathway Diagram

Introduction

Interferon Regulatory Factor 3 (IRF3) is a critical transcription factor that plays a pivotal role in the innate immune response and has emerged as an important player in neurodegenerative disease pathogenesis. As a member of the IRF family of transcription factors, IRF3 serves as a master regulator of type I interferon (IFN-α/β) responses and contributes to neuroinflammation, a hallmark of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. [@irf]

Official Symbol: IRF3 [@type] Official Full Name: Interferon Regulatory Factor 3 [@irfa] Molecular Weight: ~47 kDa (427 amino acids) [@irfb] Cellular Location: Cytoplasm (inactive), Nucleus (active) [@cgasstingirf] Gene: IRF3 (Chromosome 19q13.3) [@microglial] UniProt ID: Q00978 [@tbkirf]

Overview

IRF3 is constitutively expressed in most cell types, including neurons, astrocytes, [microglia](/cell-types/microglia-neuroinflammation), and oligodendrocytes in the central nervous system. Under basal conditions, IRF3 remains in the cytoplasm in an inactive form. Upon detection of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs), IRF3 undergoes phosphorylation and activation, leading to its nuclear translocation and transcriptional activation of interferon-stimulated genes (ISGs). [@therapeutic]

Beyond its well-established role in antiviral immunity, recent research has revealed that IRF3 activation contributes to chronic neuroinflammation in neurodegenerative diseases, making it both a potential therapeutic target and a biomarker of disease progression.

Protein Structure

The IRF3 protein contains several distinct structural domains that mediate its function:

DNA-Binding Domain (DBD)

• Located at the N-terminus (amino acids 1-115)
• Contains five conserved tryptophan repeats that form a helix-turn-helix motif
• Binds to interferon-sensitive response elements (ISRE) with consensus sequence A/GNGAAANNGAAAGT
• The DBD is highly conserved across IRF family members

Regulatory Domain (RD)

• Located at the C-terminus (amino acids 197-424)
• Contains multiple serine-rich activation motifs (SAMs)
• Mediates protein-protein interactions with co-activators and repressors

Key Phosphorylation Sites

Proline-Rich Region

• Located between DBD and RD
• Mediates interactions with SH3 domain-containing proteins
• Involved in signal transduction complex formation

Molecular Function

Activation Mechanism

The canonical IRF3 activation pathway involves:

• RIG-I-like receptors (RLRs: RIG-I, MDA5) detect viral RNA
• TLR3, TLR7/8 detect nucleic acids in endosomes
• cGAS-[STING](/proteins/sting-protein) detects cytosolic DNA

• RLRs recruit mitochondrial antiviral signaling protein (MAVS)
• MAVS forms a signaling platform on mitochondria
• TBK1 and IKKε are recruited to the MAVS complex

• TBK1/IKKε phosphorylate IRF3 at multiple serine residues
• Phosphorylation induces conformational change
• IRF3 dimerizes and exposes nuclear localization signal (NLS)

• Phosphorylated IRF3 dimerizes
• Dimers translocate to the nucleus via importin-α/β

• IRF3 dimers bind to ISRE sequences
• Recruit co-activators p300/CBP
• Activate transcription of type I IFNs and ISGs

Non-Canonical Functions

IRF3 also has transcription-independent functions:

• Can induce [apoptosis](/entities/apoptosis) through interaction with BAX
• Regulates [autophagy](/entities/autophagy) through interaction with [mTOR](/entities/mtor)
• Modulates mitochondrial dynamics

Pathway Interactions

Innate Immune Signaling

Cross-talk with Neurodegeneration Pathways

• [NF-κB](/entities/nf-kb) Pathway: IRF3 activation can induce NF-κB-dependent inflammatory genes
• cGAS-STING: Upstream activator of IRF3 in response to cytosolic DNA
• [TREM2](/proteins/trem2-protein) Signaling: Modulates IRF3 activation in microglia
• LRRK2: Kinase activity affects IRF3 phosphorylation state

Role in Neurodegeneration

Alzheimer's Disease

IRF3 plays a complex role in AD pathogenesis:

• Amyloid-beta oligomers activate IRF3 signaling in microglia and astrocytes
• IRF3-dependent production of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
• Creates chronic neuroinflammatory environment that drives disease progression

• Elevated IFN-β and ISGs observed in AD brain
• IRF3-mediated chronic type I IFN response may contribute to synaptic dysfunction
• ISG signature correlates with disease severity

• IRF3 regulates microglial phenotypic switching
• IRF3-dependent DAM (disease-associated microglia) phenotype
• Modulates phagocytic activity and cytokine production

• IRF3 inhibitors may reduce harmful neuroinflammation
• Need to balance antiviral immunity with chronic inflammation

Parkinson's Disease

In PD, IRF3 contributes to neuroinflammation in the substantia nigra:

• Oligomeric α-synuclein activates RIG-I/MAVS/IRF3 pathway
• Leads to dopaminergic neuron inflammation
• IRF3 activation in microglia surrounding Lewy bodies

• LRRK2 G2019S mutation enhances IRF3 activation
• May explain increased inflammation in LRRK2-associated PD
• TBK1-IRF3 axis links LRRK2 to innate immunity

• IRF3-dependent cytokine production contributes to dopaminergic neuron loss
• Activation of surrounding glial cells
• Potential therapeutic target for disease modification

Amyotrophic Lateral Sclerosis

IRF3 activation in ALS contributes to motor neuron injury:

• IRF3 activation in motor neurons and surrounding cells
• Induces inflammatory cascade that damages motor neurons
• [TDP-43](/proteins/tdp-43) pathology associated with enhanced IRF3 signaling

• Astrocyte and microglia IRF3 activation
• Secretion of neurotoxic factors
• Non-cell autonomous toxicity

• C9orf72 hexanucleotide repeat expansions affect IRF3 regulation
• Altered innate immune response in ALS
• IRF3 dysregulation contributes to disease pathogenesis

Other Neurodegenerative Conditions

• Huntington's Disease: IRF3 activation in striatal neurons
• Multiple Sclerosis: IRF3 in demyelination and neuroinflammation
• Frontotemporal Dementia: IRF3 dysregulation in microglia

Expression in the Brain

IRF3 expression varies across brain cell types:

Therapeutic Targeting

Small Molecule Inhibitors

• Block signal transduction to IRF3
• Reduce pathological inflammation

• Target Ser396/Ser402 phosphorylation
• Prevent IRF3 dimerization and nuclear import

• Block IRF3 nuclear translocation
• Reduce transcriptional activity

Biological Approaches

• Reduce IRF3 expression in target cells
• Cell-type specific delivery needed

• miR-200 family regulates IRF3
• Therapeutic potential being explored

• Conditional IRF3 knockdown
• Tissue-specific promoters

Challenges

• IRF3 essential for antiviral immunity
• Must preserve beneficial IFN responses
• Cell-type specific targeting required
• [Blood-brain barrier](/entities/blood-brain-barrier) penetration needed

Research Directions

Current research focuses on:

• IRF3 phosphorylation as disease biomarker
• ISG expression signatures

• Neuron-specific IRF3 functions
• Microglial IRF3 in neurodegeneration

• Optimizing timing of intervention
• Balancing inflammation and immunity

History

The discovery and characterization of IRF3 has progressed significantly:

• 1995: IRF3 first identified as transcription factor
• 2000s: Role in antiviral immunity established
• 2010s: Link to neurodegeneration discovered
• 2020s: Therapeutic targeting actively pursued

Background

The study of Irf3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• IRF3 Gene
• [TBK1 Protein](/proteins/tbk1-protein)
• MAVS Protein
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• cGAS-STING Pathway
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Microglia in Neurodegeneration](/cell-types/microglia)
• Type I Interferon Signaling